| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.61M | $80.75M | +7.3K |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | Patel Snehal61 | CEO And CFO | Buy | 3,200 | $11.12 | $35,584.00 | - | -12.6% | +100.9% | |
| Nov 21, 2024 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 1,000 | $12.91 | $12,910.00 | +0.4% | -2.9% | -37.2% | |
| Sep 26, 2024 | Patel Snehal61 | CEO And CFO | Buy | 1,500 | $14.63 | $21,945.00 | - | -17.1% | -27.4% | |
| Aug 12, 2024 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 800 | $13.85 | $11,080.00 | +0.3% | +5.1% | -7.7% | |
| Aug 6, 2024 | Patel Snehal61 | CEO And CFO | Buy | 2,000 | $13.81 | $27,620.00 | - | -7.7% | -14.7% | |
| Aug 5, 2024 | Patel Snehal61 | CEO And CFO | Buy | 5,500 | $13.18 | $72,490.00 | - | -1.3% | -11.6% | |
| Aug 2, 2024 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 1,000 | $15.15 | $15,150.00 | +0.4% | -6.3% | -22.8% | |
| Jul 23, 2024 | Patel Snehal61 | CEO And CFO | Buy | 1,500 | $15.89 | $23,835.00 | - | -16.5% | -28.4% | |
| Jul 18, 2024 | Thompson Jaye53 | VP Clinical Reg Affairs | Buy | 1,000 | $16.00 | $16,000.00 | +0.4% | -10.0% | -25.4% | |
| Jun 13, 2024 | Patel Snehal61 | CEO And CFO | Buy | 174,825 | $14.30 | $2,499,997.50 | +3.3% | -6.0% | -38.0% |